Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Acromegaly and gigantism therapeutics (2)

109 views

Published on

DelveInsight's Acromegaly and gigantism therapeutics market insight , epidemiology and market forecast 2027

Published in: Healthcare
  • Be the first to comment

  • Be the first to like this

Acromegaly and gigantism therapeutics (2)

  1. 1. ACROMEGALY AND GIGANTISM THERAPEUTICS MARKET INSIGHTS, EPIDEMIOLOGY AND MARKET FORECAST-2027 DelveInsight © 2017 | All rights reserved
  2. 2. Acromegaly The excessive GH comes from benign tumors on the pituitary Rare but serious hormonal disorder Cause - excessive growth hormone (GH) in the body Serious health complications - type 2 diabetes, high bp, cardiovascular diseases, and arthritis. DelveInsight © 2017 | All rights reserved
  3. 3. Gigantism Excessive production of GH in children leading to exaggerated bone growth and an abnormal increase in height. Reason - High linear growth due to excessive action of insulin like growth factor I (IGF-I) (epiphyseal growth plates a re open during childhood.) True gigantism is rare and usually caused by a pituitary mammosomatotroph adenoma DelveInsight © 2017 | All rights reserved
  4. 4. Key Insights To develop business strategies by understanding the trends shaping and driving the global disease scenario To understand future market competition & insightful review of key market drivers & barriers Understanding detailed global historical and forecasted disease epidemiology covering 7 MM from 2017-2027 To understand the regulatory scenario in 7 major markets i.e. US, Europe (Germany, Spain, Italy, France & UK) and Japan Disease overview including etiology, path physiology, symptoms, diagnosis, disease management & current treatment options
  5. 5. Major Market Players Chiasma Camurus Antisense Therapeutics DelveInsight © 2017 | All rights reserved
  6. 6. Emerging Therapies (Chiasma) Mycapssa (Antisense Therapeutics) ATL-1103 (Camurus) CAM2029 DelveInsight © 2017 | All rights reserved
  7. 7. Market Size by Upcoming Therapies in the 7 MM (2016-2027 ) DelveInsight © 2017 | All rights reserved
  8. 8. COMPLETE INFORMATION • For complete Information please click below Or write to us at info@delveinsight.com DelveInsight © 2017 | All rights reserved CLICK HERE
  9. 9. About DelveInsight DelveInsight, market research and consulting firm, provides end to end comprehensive solutions to the Life Science Industry. Mission Vision “Insight across the value chain” to help organizations make important business decisions through the use and analysis of actionable market intelligence To be the most trusted marketing research firm & business consulting firm worldwide. To be a renowned and premier data driven solution providers among Pharma & Biotech companies DelveInsight © 2017 | All rights reserved
  10. 10. Consulting • Asset Prioritization • Brand Optimization • Portfolio Expansion Opportunity Assessment for • Licensing • Market Access • Partnership Forecasting • Drug Sales Forecast • Indication Forecast • Late Stage Pipeline Analysis Report Store Access over 3000+ Reports • API • Market & Pipeline • Indication & Epidemiology Service Offerings Competitive analysis • Primary Analytics • News-Letters • Conference Tracking • Clinical Trials Tracking Market Intelligence • Market Size • Market Dynamics • Market Assessment DelveInsight © 2017 | All rights reserved
  11. 11. Thank you Contact Us: info@delveinsight.com +91 -11 -4568 9769 www.delveinsight.com blog/delveInsight / twitter/delveInsight LinkedIn/delveInsight DelveInsight © 2017 | All rights reserved

×